Podcast: Patel Cautions Against "Unintended Consequences" of mHealth Legislation
This article was originally published in The Gray Sheet
Executive Summary
Speaking to The Gray Sheet at the Food and Drug Law Institute's annual meeting, FDA's Bakul Patel cautioned against trying to cram too much into mobile health legislation and said the agency alongside FCC is still mulling how to proceed with standardizing wireless test beds.
You may also be interested in...
Industry: New SOFTWARE Act Provides Certainty
Rep. Blackburn’s SOFTWARE Act has changed substantially since it was first introduced and is being praised by device manufacturers for providing much needed clarity on how far FDA can go to regulate Medical and Health software.
FDA Emphasizes “Deregulatory” Efforts In Mobile Medical Apps Final Guidance
In a long-awaited final guidance, FDA affirmed its plan to practice enforcement discretion for most mobile medical apps, except those applications that present the same risks as conventional FDA-regulated devices. Some digital health stakeholders praised the guidance, while others wished FDA has waited.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.